Former US defence chief Mattis says he invested $85,000 in failed firm Theranos

Retired four-star general joined the company’s board only to be disappointed when the Silicon Valley start-up’s technology shortcomings were revealed

Former US secretary of defence James Mattis said he had believed in Theranos founder Elizabeth Holmes and invested a significant amount of his own money into the company before it failed. Reuters

Former US secretary of defence James Mattis said he believed in Theranos founder Elizabeth Holmes so much that he not only became a board member but also invested a significant amount of his own money into the company before it failed.

The retired four-star general testified on Wednesday that he admired Ms Holmes and was captivated by her promise to revolutionise blood testing, only to be disappointed when the shortcomings of the Silicon Valley start-up’s technology were revealed.

“There became a point when I didn’t know what to believe about Theranos any more,” he said. “Looking back now I’m disappointed in the level of transparency.”

He said his early enthusiasm led him in 2013 to join the company board, which was studded with other luminaries, and to put $85,000 of his own money into Theranos because he wanted some “skin in the game”.

Ms Holmes is accused of bilking more than $700 million from investors in Theranos, which was once valued at $9 billion before media exposes and regulatory investigations reduced the company to virtual rubble. Mr Mattis was asked by a prosecutor if his investment was significant.

“For someone who’d been in government service for 40 years, yes,” Mr Mattis said.

Asked how he made the choice to invest, Mr Mattis said Ms Holmes was the “sole source” of his information.

Mr Mattis, who headed the armed forces under former president Donald Trump, is among several high-profile witnesses expected to be called by the government for Ms Holmes’s trial. Former secretary of state Henry Kissinger, who was also on Theranos’s board, may testify as well as investors including News Corp chairman Rupert Murdoch.

Ms Holmes is charged with lying to investors and patients about the capabilities of Theranos machines and the company’s financial health and faces up to 20 years in prison if convicted. She has pleaded not guilty. The trial in San Jose, California, is expected to run through December.

Mr Mattis started out by telling jurors that Ms Holmes came across as “sharp, articulate, committed” when he first met her about a decade ago, before he joined the board.

“I was backstage for a speech I was going to give” in San Francisco when Ms Holmes pricked his finger for a blood test, he said. “I believe that’s when I first saw the machine, a box-like device,” Mr Mattis said.

The general said Theranos’s goal of performing blood tests in compact equipment had appeal for military applications.

“I’d been rather taken with the idea of just one drop of blood in a remote” area to test for a broad array of problems, Mr Mattis said. It could be most helpful in triage “if it could do what she said she could do”.

The general was questioned about a Theranos board meeting he attended in October 2013 at which Ms Holmes delivered an upbeat report on the company’s technology. A prosecutor asked if he knew then that the company was routinely relying on blood analysers manufactured by other companies – as other witnesses have testified.

“It would’ve tempered my enthusiasm significantly,” Mr Mattis said, but that he had taken it on Ms Holmes’s “good faith” that the Theranos analysers “could deliver a lot of capability”.

In 2011, Mr Mattis had committed to helping Ms Holmes get Theranos machines introduced as a “pilot project” in military use. “I was trying to get the military side to open the door,” he said.

“It was something I didn’t want to have people go to sleep on and not take advantage of it. But it was never relied on by soldiers or officially deployed 'in theatre',” Mr Mattis said, describing the process as getting tied up in bureaucracy. Prosecutors have told the jury Ms Holmes made grandiose claims starting in 2009 that Theranos machines were used by the military.

Mr Mattis said he was not aware of Theranos analysers ever being actively used on military helicopters or to provide medical assistance to soldiers in clandestine operations. “I’m not aware of it,” he said repeatedly when questioned by a prosecutor.

By early 2016, Mr Mattis said, he was struggling with his instinct to support Ms Holmes given his misgivings after revelations about the technology – and Ms Holmes’s equivocation in response. Shortly afterwards, his support evaporated. “I couldn’t see why we were being surprised on such fundamental issues,” he told the jury.

Kevin Downey, a lawyer for Ms Holmes, tried to soften the blow of Mr Mattis’s testimony by getting the general to acknowledge under cross-examination that he was not in a position to evaluate Theranos technology because he did not have a scientific or engineering background.

In various questions from Mr Downey about his service on the board, Mr Mattis displayed a deep interest and involvement in Theranos. But the former commander of US Central Command covering the Middle East struggled to remember a few details. “We might’ve had a few things going in the Mid-East at the time,” Mr Mattis said, a response met by laughter in the courtroom.